Mitral valve cardiac restoration system PASCAL

The latest advancement from Edwards Lifesciences in transcatheter mitral therapies: The PASCAL Precision system Discover the difference with the PASCAL implants Designed for patient-focused care Designed to reduce leaflet stress and increase open orifice area enabling low gradients Features a narrower design profile to help you optimize your treatment of degenerative mitral regurgitation Features Treat your patients with degenerative mitral regurgitation with the latest transcatheter mitral innovation from Edwards Lifesciences Predictable implant release Deploy the implant with confidence The MR reduction you see before implant release is the result you can achieve for your patient after release Overview of the PASCAL Precision system Advanced catheter technologies facilitate smooth navigation and implant deployment Clinical evidence CLASP IID Randomized Control Trial (RCT): The first and only RCT to directly compare two contemporary TEER therapy in patients with DMR. CLASP IID Registry: A first-of-its-kind registry to evaluate the PASCAL system in DMR patients with complex anatomy. CLASP: The first international, multicenter study to evaluate the safety and clinical outcomes of the PASCAL system. CLASP IID trial The objective of this prospective, multicenter, randomized, controlled pivotal trial is to evaluate safety and effectiveness in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team. CLASP IID Registry The objective of this prospective, multinational registry within the construct of the CLASP IID trial is to study significant symptomatic DMR patients